AIM Vaccine (Stock Code: 06660) is a Hong Kong Main Board-listed company committed to producing trustworthy vaccines to safeguard global health. In terms of industrial scale, it ranks as China's second-largest and privately-owned largest full-industry-chain vaccine group, a leading enterprise in China's vaccine sector, and a top-three leader in the country's mRNA vaccine field.
Currently, AIM owns four wholly-owned licensed vaccine production enterprises and three central research institutes. It is also one of only two human vaccine enterprises in China with strategic access to P3 laboratories, as designated in the National 14th Five-Year Plan by the National Development and Reform Commission (NDRC). Furthermore, AIM is the world's largest manufacturer of hepatitis B vaccines and the second-largest manufacturer of rabies vaccines globally.
Serum-free Rabies Vaccine: As the world’s first rabies vaccine with no bovine serum added throughout the entire process of cell culture and virus culture, it markedly enhances product safety.
Human Diploid Cell Rabies Vaccine: has pioneered the breakthrough of the low virus titer bottleneck in traditional processes and solved the technical challenge of high-titer virus culture in large-scale reactors. It has also introduced optimized and innovative purification processes using
an ultra-large ultrafiltration and chromatography system to enhance antigen purity, resulting in substantial improvements in both product quality and safety.
The unblinding and statistical analysis of the Phase III clinical trial for the 23-valent pneumococcal polysaccharide vaccine have been completed, and the clinical study report has been obtained.
Inactivated Hepatitis A Vaccine (Human Diploid Cell): One of only two commercially available inactivated hepatitis A vaccines on the current market.
We have developed two sizes of recombinant HBV vaccine products, 10μg/0.5ml and 20μg/0.5ml per dose. The 10μg dosage recombinant HBV vaccine is allowed to be administered in all age groups, including newborns, children and adults, and is the only yeast-derived hepatitis B vaccine currently in the Chinese market for use by the entire population.
The 20μg dosage recombinant HBV vaccine has been approved to be administered in people in the age group of 16 years old and above. Its unique 0.5ml small package reduces the vaccination time and pain time and provides a better vaccination experience, and we are the only enterprise which provides 0.5ml small package of 20μg hepatitis B vaccine in the current domestic market, which fills the gap in the domestic market. Our recombinant HBV vaccine series products have maintained a 100% pass rate in lot release quality audits of NIFDC since their approvals.
The freeze-dried human rabies vaccine (Vero cell), one of our major products, is an injectable vaccine administered under the intramuscular route to persons of all ages to prevent rabies after exposure or when in a high-risk environment of exposure to rabies. We manufacture this vaccine product in AIM Rongyu, which obtained the NDA approval in September 2007 and the GMP certificate in June 2008.
